Article ID Journal Published Year Pages File Type
6100460 Journal of Crohn's and Colitis 2011 8 Pages PDF
Abstract
Second-line anti-TNFα therapy with adalimumab is effective at both inducing remission and maintaining response in CD patients who have failed infliximab, regardless of the reason for infliximab failure.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Preview
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
Authors
, , , , ,